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Abstract
Vascular leakage, or increased vascular permeability, is a common but important pathological process for various
critical diseases, including severe trauma, shock, sepsis, and multiple organ dysfunction syndrome (MODS), and has
become one of the most important causes of death for intensive care units (ICU) patients. Currently, although there
has been some progress in knowledge of the pathogenesis of these vascular disorders, the detailed mechanisms
remain unclear, and effective prophylaxis and treatment are still lacking. In this study, we aimed to provide a review
of the literature regarding the regulatory mechanisms and prophylaxis as well as the treatment of vascular leakage
in critical diseases such as severe trauma and shock, which could be beneficial for the overall clinical treatment of
vascular leakage disorders.
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Background
Capillary leak syndrome (CLS) refers to a series of syn-
dromes with clinical manifestations of serious tissue
edema, such as severe hypoproteinemia, hypovolemia and
hypoperfusion, which is caused by the massive leakage of
plasma proteins and intravascular fluid due to injuries to
the vascular endothelium as well as increased vascular
permeability [1]. The high mortality of CLS patients is
believed to be associated with the non-specific clinical
manifestations and the rapid progression of these disor-
ders in the acute-onset phase [2]. Dhir et al. [3] found that
the 5-year survival rate in CLS patients is approximately
70% and that 75% of the deaths occur in the acute-onset
phase [4]. In addition, research has indicated that the 10-
year mortality of CLS patients is approximately 34%, while
deaths that occur in the intensive care units (ICU) are
caused by both the acute onset and the complications of
CLS, which account for 80% of the total mortality [5].
Under normal physiological conditions, water and elec-
trolytes could pass through the capillary wall into the inter-
stitial space instead of the plasma albumin, while proteins
with molecular weight larger than 200 kD, or even 900 kD
in some particularly severe circumstances, could also pass
through the wall into the interstitial space. This physio-
logical event occurs in cases of severe trauma, sepsis,
cardiopulmonary bypass surgery (especially in infant
cardiopulmonary bypass surgeries), reperfusion injury, ven-
omous snake bites, acute lung injury, acute respiratory
distress syndrome (ARDS), burns and drug toxicity (such as
recombinant interleukin-2 and docetaxel). In certain drug
toxicities, the mononuclear-phagocyte system, endothelial
cells and neutrophils are excessively activated, resulting in
the release of inflammatory cytokines and immune reac-
tions, in which then produces injuries to the capillary endo-
thelium, broken intercellular junctions and vascular leakage
[6], which ultimately causes CLS. The major adverse effects
of CLS include alveolar edema, restricted gas exchange and
hypoxia, all of which aggravate injuries to the capillary
endothelium cause edema in major organs such as the
brain, the heart, the liver and the kidneys with the struc-
tures and functions that are damaged and that ultimately
result in multiple organ dysfunction syndromes (MODS).
Once that happens, the patient’s condition becomes more
serious and includes higher risk for death [7]. Therefore,
investigating the pathogenesis of vascular leakage or
increased capillary permeability is of great significance for
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the prophylaxis and treatment of CLS. In this review, we
will focus on newly identified regulatory mechanisms, and
the prophylaxis and treatment of vascular leakage in critical
clinical diseases such as shock.
Pathways and regulatory mechanisms of vascular
leakage
The vascular endothelium is composed of monolayer cells
on the surface of vascular lumen and on the extracellular
matrix in the deep layer. The vascular endothelium is a
semi-permeable barrier between the vascular wall and the
blood and controls the exchange of macromolecules and
liquids between the interstitial fluid and blood. Generally,
the occurrence of vascular leakage occurs through one of
two pathways: the paracellular pathway, which refers to
material that is diffused by passive transport through gap
junction communication channels that are formed by
intercellular junctions to the adjacent cells [8]; or the
transcellular pathway, which refers to macromolecules
that are transferred out of the vessel by endothelial cells
instead of the intercellular junctions [9]. Although these
two pathways can simultaneously exert synergistic or indi-
vidual effects, previous quantitative analysis has confirmed
that the paracellular pathway is the preferable pathway in
cases of vascular leakage [10].
Paracellular pathway
The paracellular pathway, also known as the interen-
dothelial junction, refers to endothelial cells that are
stimulated by an endogenous or an exogenous material.
This stimulation of the paracellular pathway generates a
series of variations in signal pathways to widen the inter-
cellular gap by regulating the contraction of the endo-
thelial cytoskeleton or by altering the intercellular
junctions, which results in increased vascular permeabil-
ity. There are three main types of endothelial cell junc-
tions: tight junctions, adherens junctions between the
cells, and adherens junctions between the endothelial
cells and the basement membranes. Since the structure
and protein composition of the tight junction and the
adherens junction of endothelial cells were recently in-
troduced in a summary report [11], we will mainly dis-
cuss the effects that these two kinds of junctions have in
cases of vascular leakage.
The effect of the tight junction in vascular leakage
Tight junction proteins include the junction adhesion mol-
ecule (JAM), the occludin, the claudin, the zona occludens
(ZO) and the cingulin. The JAM-1 can secure the stability
of the tight junction and can regulate the permeability of
the endothelial barrier by potentially mediating the con-
struction of the reticular structure of the macromolecular
complexes of the plasma membrane. Orlova et al. [12]
found that the JAM plays an important role in regulating
the functions of endothelial actin and myosin, (i.e., when
the JAM gene is knocked off, the level of actin and the ac-
tivity of myosin light chain phosphatase (MLCP) decreases,
which leads to an increase in the level of phosphorylated
myosin light chains and the formation of actin stress fibers.
Occludin is not only a major composition of the tight
junction but can also regulate the functions of the tight
junction. Occludin can regulate the formation and decom-
position of the tight junction and can maintain the integ-
rity of the tight junction by adjusting the activity of the
transmembrane proteins (actin and myosin) through the
protein kinase C (PKC), the mitogen-activated protein kin-
ase (MAPK) and the myosin light chain kinase (MLCK).
Wong et al. [13] has shown that only phosphorylated
occludin can combine with the tight junction. For occludin
phosphorylation, serine/threonine are usually phosphory-
lated at the carboxyl terminal. Most of the phosphorylated
occludin is distributed in the tight junctions, while the
occludin and few phosphorylated residues is mainly distrib-
uted in the basement membrane of the cytoplasm [14].
Blasig et al. [15] found an increase in the transport of un-
charged molecules by the tight junction barrier after exci-
sion of the carboxyl terminals on the occludin gene
because of cell transfection. However, no variation has
been found in trans-epithelial electrical resistance (TEER)
with an increased permeability of the tight junction, which
indicates that the increased permeability of the barrier is
caused by an interruption of the mutual effect between
tight junction proteins, instead of an increase in the TEER.
There are 24 molecules with highly homologous se-
quences in the claudin family that are named claudin −1
to −24 and that have molecular weight ranging from 20 to
27kD [16]. Binding sequences, located in the C-terminal
of all claudins, can directly incorporate other tight junc-
tion proteins in the cytoplasm [17], such as ZO-1, ZO-2,
ZO-3, which are proteins with PDZ domains as well as as-
sociated PALS-1 tight junction proteins. The mutual effect
between ZO-1 and ZO-2 could lead to an indirect inter-
action between claudins and actin [18]. The dense band,
composed of claudin polymers, could accelerate the for-
mation of barriers. Van Itallie et al. [14] found that the
phosphorylated S208 locus on the C-terminal of the cyto-
plasm of claudin-2 can influence the location of claudin-2
without changing the binding with ZO-1 or ZO-2. Recent
research has confirmed that the extracellular domain of
claudin-1 can not only affect the assembly of the tight
junction but can also suppress its barrier functions [19].
Interestingly, this domain of claudin-1 is closely connected
to occludin, which suggests that there might be a direct
mutual effect between these two proteins, and this mutual
effect is expected to be confirmed in future studies.
ZO-1 and ZO-2, which are two intermediate connec-
tors, can closely bind the claudin, the occludin, and the
JAM with actin and is also believed to be one of the key
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functions of the tight junction. Phosphorylation of the
ZO-1 protein is intimately associated with the location
of the intercellular tight junction and the permeability of
cells, and excessive phosphorylation of the ZO-1 protein
can relax the binding between occludin, leading to a
decrease in function. In cells that lack the ZO-1/ZO-2
genes, the content of tight junction-related proteins
(such as claudin) is relatively low [20], and the functions
of the tight junction are also affected; however, the ex-
pression of tight junction-related proteins increases and
the functions of the tight junction return to normal
when the cells are transfected with ZO-1/ZO-2 genes.
According to the latest research, Wang et al. [21] found
that blood-brain barrier injuries caused by microwave ir-
radiation were also associated with the decomposition of
the tight junction and decreased function of the ZO-1
gene. Tyr-phosphorylation of occludin occurs because of
microwave irradiation, which weakens the mutual effect
between the occludin and the ZO-1 and results in a
widened gap and a decomposition of the tight junction.
Further studies have revealed that this process might
produce these results by activating the vascular endothe-
lial growth factor/fetal liver kinase 1 - extracellular
signal-regulated kinase (VEGF/Flk-1-ERK) pathway.
The function of adherens junctions between cells in cases of
vascular leakage
The adherens junction is one of the intercellular junctions
results from the interaction between cadherin and the ad-
jacent cellular membrane. Cadherin can bind with catenin,
a kind of cytoplasmic protein, which is further connected
to the cytoskeleton complexes (i.e., the actin filament or
the microtubules) to stabilize the intercellular junctions
[22]. In particular, vascular endothelial-cadherin (VE-cad-
herin) refers to the endothelial cadherin that is specifically
expressed by vascular endothelial cells. As the most im-
portant adhesive composition of endothelial adherens
junctions, VE-cadherin can exert its functions only by way
of the VE-cadherin-catenin complex, which is composed
of VE-cadherin, α-catenin, β-catenin and P120-catenin,
etc. The VE-cadherin-catenin complex is also mediated by
the targeted molecules of substances that can increase
microvascular permeability [23, 24]. Multiple substances,
such as VEGF, TNF-α, platelet activating factor, and
thrombin or histamine, can induce the tyrosine phosphor-
ylation of VE-cadherin, α-catenin and β-catenin to in-
crease the vascular permeability [25, 26]. In EDTA-treated
endothelial cells, a decrease in binding activity is seen be-
tween the VE-cadherin and the cytoskeleton [27, 28],
which indicates that Ca2+ could protect the VE-cadherin
from being hydrolyzed by proteolytic enzymes.
It should be noted that the functions of tight junctions
also depend upon the integrity of intercellular adherens
junctions. Caused by removal of extracellular Ca2+,
loosened cables in adherens junctions will open the tight
junctions [29]. However, Maiers et al. [30] indicated that
by blocking the binding between ZO-1 and α-catenin,
the stability of the adherens junctions was not affected,
but damaged the endothelial barrier functions and
destroyed the assembly with variations in ZO-1 motility
and the structure of the actin cytoskeleton. Thus, the re-
sults suggest that binding between ZO-1 and α-catenin
might be a new coupling mechanism for adherens junc-
tions in the endothelial barrier.
Transcellular pathway
Macromolecular substances are transferred out of the ves-
sels through endothelial cells, instead of through the inter-
cellular gap. Feng et al. [31] found that plasma proteins
and other macromolecular substances can be diffused out
of a morphologically intact capillary without any intercel-
lular gaps. In addition, they also found alveoli with vesicles
in the capillary endothelial membrane in ultrathin sections
that were 14 nm in height, which could have been caused
by pinocytosis. Macromolecular tracers can be rapidly dif-
fused out of the vessel from the capillary vein through
vesicular-vacuolar organelles (VVOs) [32, 33]. The protu-
berance, or small cavity formed by the cytoplasm of the
capillary endothelial cells, is possibly associated with the
regulation of focal blood velocity and flow and the ex-
change, synthesis, release, transformation of material and
the inactivation of active substance. The angiotensin con-
verting enzyme also exists in this small cavity. In addition,
there are various proteins and enzymes distributed on the
endothelial cells that express many receptors with diversi-
fied functions and structures. In addition to the vesicle
transporter, aquaporin (AQP) on the endothelial mem-
brane has been found to participate in the transcellular
pathway.
Aquaporin
It had been long been believed that water could not pass
through the membrane due to the hydrophobic property
of the lipid bilayer in the membrane. However, it has been
recently found that a 28 kD protein family on the mem-
brane, namely, the AQP protein, that has a structure like
other channel proteins, can adjust the transcellular perme-
ability of water. The basic function of AQP is to mediate
the transcellular transport of free water molecules. The
major difference from other ion channels is that the os-
motic pressure gradient only regulates the transport of
water (i.e., the water molecules could be diffused through
the AQP along the osmotic pressure gradient) instead of
the so-called “turn-on” or “turn-off” phases. Thus, water
molecules could be directly allowed into and out of the
cells. Once the endothelial cells are injured, the expression
of AQP increases, which augments capillary permeability
and is believed to be closely associated with the onset of
Duan et al. Military Medical Research  (2017) 4:11 Page 3 of 11
hydrocephalus. To date, there are 13 kinds of proteins that
have been identified as members of the AQP family, which
include AQP0 to AQP12. These 13 AQP genes exert
diversified physiological functions due to the different
expression sites with similarities in permeability [34].
The transcellular pathways of water are distributed in
all tissues but are mainly in epithelial and endothelial
cells that have functions related to the secretion and the
absorption of fluid. These proteins participate in the
regulation of secreting and absorbing water as well as in
the homeostasis between extra- and intracellular fluid
volume.
Distributed in the outer medullary descending vasa-recta
(OMDVR), the AQP1 is related to the mechanism of urin-
ary concentration. AQP1−/− mice showed a deficiency in
urinary concentration due to the damaged water transport
pathway that was energized by osmotic pressure and ex-
hibited symptoms such as polyuria, hypotonicity of the
urine, decreased response to vasopressin, significantly en-
larged OMDVR and adaptive capillary wall reconstruction.
The expression of AQPs is diversified based on differ-
ent places in the lung, (e.g., the AQP1 gene is mainly
expressed in the capillary endothelium; the AQP3 gene
is mainly expressed in the epithelial cells of both the
nasopharynx and the airway; the AQP4 gene is mainly
expressed in the basal-lateral membrane in the epithelial
cells of the airway; and the AQP5 gene is mainly
expressed in the epithelial cells in the alveoli). Both the
AQP1 and the AQP5 genes can regulate the osmotic
water transport in the capillaries of the airway, but do
not affect the humidification or the liquid homeostasis
on the surface of the airways.
In the thoracic tissues, the AQP1 gene is expressed in
the endothelial cells of both the visceral and cervical
pleura as well as the mesothelial cells in the cervical
pleura to regulate the osmotic pressure balance of fluid
inside and outside the thoracic cavity. Researchers have
found that the AQP1 gene is intimately associated with
the extent of cardiac necrosis in cardiopulmonary bypass
and infarction models, which suggests a potential rela-
tionship between the myocardial ischemia and the main-
tenance of myocardial edema [35].
Expressed by hepatic cells, the AQP8 gene is mainly
located in the cellular vesical. During the process of bile
secretion, the AQP8 gene in the membrane is trans-
ported to the canalicular membranes, which are induced
by cAMP and increase the water permeability of the ap-
ical membrane, thus achieving water transport [36]. In
addition, Drobná Z et al. [37] found that the bile secre-
tion by bile canaliculi is synergistically regulated by the
AQP8 gene and hepatic sinusoidal AQP9 gene, which
mediates water transport between the hepatocytes and
the blood in the hepatic sinusoidal endothelium. Distrib-
uted on the basal membrane of intrahepatic
cholangiocytes, AQP4 can maintain the equilibrium of
water permeability between the apical area and the basal
membrane of cholangiocytes and mainly regulates the
water permeability of the basal membrane.
The permeability of the blood-brain barrier in brain tis-
sues is also associated by some subtypes of AQP. Teng et
al. [38] found a significant and positive correlation
between the expression of AQP4 mRNA and the perme-
ability of the blood-brain barrier in mice after cerebral
hemorrhage. Ke et al. [39] identified focal changes in the
expression of AQP4 mRNA in cases hydrocephalus with
concomitantly damaged blood-brain barriers, while there
were no significant changes in cases of hydrocephalus that
were caused by diffuse brain injuries without any damage
to the blood-brain barriers. In addition, the research by
Liu et al. [40] indicated that overexpressed AQP9 gene
after a cerebral hemorrhage was closely associated with
the damage of the blood-brain barrier and the formation
of hydrocephalus. The possible explanatory mechanism is
that, while in an ischemic and hypoxic environment, the
Na+-K+-ATPase of the membrane in the brain tissues is
destroyed and the balanced ion exchange in the mem-
brane is broken, thus activating the expression of the
AQP9 gene, which perceives changes in osmotic pressure.
Vesicle
Under normal physiological conditions, the transport of
bio-macromolecules in the blood is strictly restricted by
the endothelial barrier, which makes the paracellular
pathway only permeable to small molecular substances,
such as glucose or blood urea nitrogen, while it is im-
possible for macromolecular substances like albumin to
pass through the membrane directly. The transport of
such macromolecular substances depends on the vesi-
cles, a kind of cellular structure, by which the molecules
awaiting transport will be absorbed and then delivered
to the organelles of the target cell or extracellularly. This
pathway plays a crucial role in maintaining the normal
colloid osmotic pressure of the tissues. Plasmalemmal
vesicles that include the caveolae and fenestrae are cur-
rently being studied.
Like the subcellular structure, the caveola is a flask-
shaped, cave-like invagination specifically spread on the
surface of the cytoplasmic membrane with a diameter
that ranges from 50 to 100 nm. Caveolae are widely
spread throughout various cells but are rich in endothe-
lial, epithelial and smooth muscle cells with the exist-
ence of the Caveolin molecule as the representative
feature [41]. Caveolae mainly participate in the endo-
cytosis and pinocytosis of macromolecular substances
and in signal transduction [42]. As a kind of integrin
membrane protein with a molecular weight that ranges
from 21 to 24 kD, caveolin plays important roles in
maintaining the morphological integrity, structure and
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function. Currently identified members of caveolins family
include caveolin-1ɑ, caveolin-1β, caveolin-2ɑ, caveolin-2β,
caveolin-2γ and caveolin-3 [43]. Caveolin-1 and caveolin-2
are expressed in most cells (e.g., epithelial cells, endothe-
lial cells, adipocytes, fibroblasts, smooth muscle cells,
etc.), especially in the cells of the cardiovascular system,
where the expression of caveolin-1 and caveolin-2 can be
directly observed. However, caveolin-3 is specifically
expressed in muscle cells (i.e., smooth muscle cells,
skeletal muscle cells, cardiac muscle cells, astrocytes,
chondrocytes, etc.) and is intimately associated with the
synthesis of muscle cells [44].
Fenestrae, with a diameter of 107 ± 1.5 nm, are round-
shaped, sieve plate-like, and clustered transcellular pas-
sages [45]. However, Xu et al. [46] showed that the diam-
eter of fenestrae was proven to be 60–80 nm . Research
has confirmed that these fenestrae account for 20–50% of
the surface area of endothelial cells and act as the bi-
directional guardian in the regulation of the transcellular
passage for the transport of macromolecular substances
such as albumin [46]. Under electron microscopy, Ryan et
al. [47] found that the transport of macromolecular sub-
stances like albumin was mainly regulated by a layer of
polysaccharide-protein complexes in the domain of fenes-
trae that were covered on the surface of the endothelial
cells. These complexes included oligosaccharide chains of
glycoproteins and proteoglycans with relative GAG, such
as chondroitin sulfate and heparin sulfate [48]. In addition,
the location of different fenestrae varies. Open fenestrae
that lack any structural obstructions are mainly located in
the thin peripheral cytoplasm while the complexes of
multi-folded fenestrae are organized as labyrinthine struc-
tures that are found in the proximity of the perinuclear
area [49]. Labyrinthine fenestrae constitute about one-
third of the total porosity of endothelial cells.
Signal mechanisms and major inducing factors of
vascular leakage
Signaling mechanisms of vascular permeability
Cell-cell junctions and cell-basal lamina junctions are all
connected by cytoskeletal proteins. Variance in cytoskel-
etal functions can lead to changes in the adhesive states
of intercellular and basal lamina cell junctions that can
induce the rearrangement of skeletal proteins through
the mechanism of signal transduction, which alters the
permeability of endothelial cells.
Research has indicated that actin filaments are pre-
sented in cells as filamentous actin, F-actin, and global
actin, G-actin. Under normal physiological conditions,
the actin filaments in endothelial cells are mainly spread
in the nuclear and peripheral areas of cells and form a
compact peripheral band. By activating the ATPase that
is located in the globular head of the myosin heavy
chain, the phosphorylated MLC gene can generate the
energy needed to mobilize the F-actin filament in the
actin cytoskeleton with a compact peripheral band of
microfilaments that has disappeared. This process forms
the stress fiber that is composed of a non-polar and
single-rowed actin filament with altered cellular morph-
ology, which results in enlarged and increased intercellu-
lar gaps and augmented permeability [50]. The MLCK
directly transferred into the capillaries that are isolated
for culture can induce a significant increase in endothe-
lial cell permeability, while an MLCK inhibitor, such as
ML-7 or BAPAT, can protect the functions of endothe-
lium by suppressing the increase in EC permeability that
is induced by thrombin. Research has confirmed that an
increase in the permeability of the intestinal mucosal
barrier at an early stage with the augmentation of pro-
tein expression of the MLCK and the phosphorylation of
the MLC, specifically MLC-inhibited phosphorylation
mediated by MLCK, can significantly reduce the in-
creased amplitude in the permeability of the intestinal
mucosal barrier and alleviate the tissue injuries and the
changes in ZO-1 [51]. In addition, calyculin, the MLCP
inhibitor, can significantly increase capillary permeability
and simultaneously sustain the phosphorylation level of the
MLC gene. Various signal pathways (Fig. 1) are involved in
these regulatory mechanisms: a) the Ca2+-PKC/CaM
pathway can regulate vascular permeability through modifi-
cation of the tight junction by controlling the phosphoryl-
ation level of MLC by MLCK; b) the cGMP-PKG pathway
can regulate vascular permeability by regulating AQP activ-
ity and tight junctions through controlling the phosphoryl-
ation level of MLC by MLCK; c) the cAMP-PKA pathway
can regulate vascular permeability by adjusting the activity
of MLCP and AQP; d) the PTK-MAPK pathway can affect
vascular permeability by regulating the tight junctions by
focal adhesion kinase (FAK); e) the small G protein (SGP)
pathway can regulate vascular permeability by adjusting the
tight junction, the adherens junctions and the vesicles
through Rho and Rac GTPases and CDC42.
Major inducing factors for vascular leakage
Signal transduction mechanisms affecting the permeability
of the vascular endothelium are relatively complicated,
and various inducing factors such as the inflammatory
mediators of Ca2+, nitric oxide (NO), vascular endothelial
growth factor (VEGF) and thrombin, can alter the
junction-related cytoskeleton (e.g., actin and myosin),
which further influences the contractile and morpho-
logical variations of endothelial cells.
VEGF
A type of glycogen, VEGF were first purified from the in
vitro culture solution of astrocytes in the follicles of the pi-
tuitary gland and were named by Ferrara in 1989 [52].
VEGF can affect vascular permeability through several
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pathways. VEGF destroys the intercellular adherens junc-
tion and tight junction to increase vascular permeability
and can promote the phosphorylation of Y658 and Y731,
VE-cadherin, to destroy the mutual junction between VE-
cadherin and β-catenin [53]. In addition, VEGF can break
the intercellular tight junctions through the VEGFR-2
pathway, which precipitates vascular leakage [54–56].
Moreover, VEGF can increase vascular permeability by
Fig. 1 The mechanism of signaling transduction of vascular permeability. NO, Nitric Oxide; VEGF, vascular endothelial growth factor; TNF, Tumor
necrosis factor; PKC, Protein kinase C; PDE, Phosphodiesterase; cGMP, Cyclic guanosine monophosphate; PKG, Protein kinase G; cAMP, Cyclic adenosine
monophosphate; PKA, Protein Kinase A; PTK, Protein Tyrosine Kinase; RhoA, Ras homolog gene family member A; ROCK, Rho-associated coiled-coil-
containing protein kinase; ROS, Reactive oxygen species; Rac, Ras-related C3 botulinum toxin substrate 1; PAK, p21-Activated Kinase; Cdc42, Cell division
control protein 42; AR, Androgen receptor; MLC, Myosin light chain; MLCP, Myosin light chain phosphatase; MLCK, Myosin Light Chain Kinase; MAPK,
Mitogen-activated protein kinase; TNFR1, Tumor necrosis factor receptor 1. a) Ca2+-PKC/CaM pathway, the vascular permeability is regulated in the tight
junction by controlling the phosphorylation level of MLC by MLCK; b) cGMP-PKG pathway, the vascular permeability is regulated by AQP activity and
tight junctions through controlling the phosphorylation level of MLC by MLCK; c) cAMP-PKA pathway, the vascular permeability is regulated by
adjusting the activity of MLCP and AQP; d) PTK-MAPK pathway, the vascular permeability is affected by regulating the tight junctions by FAK; e) SGP
pathway (small G protein), the vascular permeability is regulated by adjusting the tight junction, the adherens junctions and the vesicles by Rho and
Rac GTPases and by CDC42
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separating the intercellular junctions through the MAPK
and PKC pathways. VEGF induces the formation of fenes-
trae and caveolae in the cytoplasm of endothelial cells to
promote the penetration of the solute through the mem-
brane. VEGF can induce the invagination of the mem-
brane to form vesicles, which leads to an increase in
fenestrae in the microtubular system in cells and the
formation of penetrative gaps in the cytoplasm, which are
extended from the integration of the luminal membrane
to the basal lamina, which increases the vascular perme-
ability of the endothelium [57, 58].
NO
NO can induce an increase in vascular permeability
through two main ways. NO induces the cyclic guanosine
monophosphate -protein kinase G (cGMP-PKG) signal
pathway to increase vascular permeability, which is the
most frequently seen pathway. Interactions between NO
and soluble guanylyl cyclase (sGC) can induce the forma-
tion of cGMP to stimulate the PKG and the MAPK genes,
thus increasing vascular permeability [59]. NO also in-
creases vascular permeability through the S-Nitrosation on
the sulfhydryl group of the relevant protein to destroy the
adherens junctions, which increases vascular permeability.
S-Nitrosation on the sulfhydryl group of the relevant pro-
tein is similar to phosphorylation and depends on some
target proteins to stimulate or inhibit some biological pro-
cesses [60]. Research has shown that variations in vascular
permeability caused by S-Nitrosation correlate to the rapid
decrease of the levels of two kinds of adherens junction
proteins: β-catenin and p120-catenin [61, 62]. The increase
of NO caused by tumor necrosis factor -α (TNF-α) and
active platelet factors causes the upregulation of S-
Nitrosation on the sulfhydryl group of the relevant protein.
Cytokines
Research has shown that interleukin and TNF play im-
portant roles in regulating shock-related vascular perme-
ability. Persistent intravenous or intraperitoneal injections
of IL-2 can cause “vascular leakage syndrome,” where
extracellular fluid is rapidly accumulated and leads to asci-
tes and pulmonary edema. In the latest research by
Puerta-Guardo, the results indicated that significant in-
creases in the expression of cytokines such as IL-6, IL-12,
p70, TNF-α and prostaglandin E2 (PGE2) in septic shock
could alter vascular permeability by destroying the tight
junctions. Wiggins-Dohlvik et al. [63] found that TNF-α
can separate the tight junctions by decomposing ZO-1 to
increase vascular permeability.
Microparticles (MPs)
MPs refer to those vesicles generated by cells of 0.1 to
1 μm [64]. Lacking nuclei and the comprehensive ability
of cells, MPs contain cytoskeletal proteins and are
covered on the surface by certain amounts of phosphati-
dylserine [57]. MPs were once called “platelet dust” and
were first discovered at the beginning stages of blood
clotting. Current research has shown that MPs are not
simply the production of invalid cellular fragments. The
literature has confirmed that MPs could reduce vascular
generation, promote oxidative stress, weaken vasodila-
tory effects and generate reactive oxygen species (ROS).
Theoretically, MPs can be generated by all cells, which
has been proven by some reports, but most studies be-
lieve that MPs originated from platelets, leukocytes and
endothelial cells [65, 66]. Currently, there are many
studies that are focusing on the origination of MPs from
platelets. In recent years, the research has confirmed
that MPs play an important role in promoting vascular
leakage and maintaining equilibrium in homeostasis.
The existing studies indicate that the MPs with cyto-
kines or small RNA sequences can increase vascular
permeability by acting on the vascular endothelium.
New methods for the prophylaxis and treatment
of vascular leakage
Methods for the prophylaxis and treatment of vascular
leakage mainly include both conventional methods and
newly developed targeted measures. Conventional methods
include the correction of acidosis and glucocorticoid ther-
apy, while the targeted measures for the variations in vas-
cular permeability secondary to septic shock is performed
on the inducing factors that cause the increase in vascular
permeability and on the therapeutic targets. The main
methods in this targeted approach include reducing the
inducing factors and inhibiting the therapeutic targets to
cause an increase in vascular permeability.
Preventing vascular leakage by VEGF antagonism
Angiopoietin-1 (Ang-1 or ANGPT1) is a newly identified
endogenous protein factor that can antagonize the vascu-
lar leakage caused by VEGF and inflammatory mediators.
Gamble et al. (2000) indicated that ANGPT1 can offset
approximately 70% of the vascular leakage caused by
VEGF [67]. Thurston et al. (2000) found that the ANGPT1
gene can stabilize the structure of the vascular wall can
promote both the spread of endothelial cells and the for-
mation of tuber-like structures [68]. Through specifically
binding with TIE-2, the ANGPT1 gene can cause the
phosphorylation of its receptor and subsequent signal
transmission. Removal of the ANGPT1 and TIE-2 genes
can lead to vasodilation and increased vascular permeabil-
ity, which is related to the activation process of FAK by
the phosphatidylinositol 3-kinase (PI3K) [69].
Protein phosphatases 1 (PP1), as an effective Src-1 inhibi-
tor that can significantly decrease vascular permeability.
The increased expression of Src-1 and its phosphorylation
were positively correlated to the levels of VEGF and were
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negatively correlated to the ANGPT1 gene [70]. The inhibi-
tory effect of PP1 on Src-1 may occur because of the down-
regulation of VEGF and the upregulation of the ANGPT1
gene, which may further enhance the tight junctions and
reduce vascular permeability [71].
Reducing the vascular permeability by controlling the
release of NO
Sphingosine-1-phosphate receptor 2 (S1pr2) can sup-
press the increase in shock-related vascular permeability
by inhibiting the endothelial nitric oxide synthase
(eNOS). Endothelial cells lacking S1pr2 exhibit severely
damaged adherens junctions. Cui et al. [72] found that
S1pr2 can protect the vessels by inhibiting the activity of
protein kinase B (AKT), which is an activating enzyme
for the eNOS. Previous studies on multiple kinds of cells
indicated that the mammalian target of rapamycin
(mTOR) can mediate the upregulation of the expression
of the VEGF gene caused by hypoxia- inducible factor-1
alpha (HIF-1ɑ) and that the expression of mTOR is reg-
ulated by either PI3K/Akt or PKCδ. Choi et al. [73]
found that rottlerin, a kind of inhibitor of PKCδ, can re-
sult in the suppression of the activity of the upstream
signal of the PI3K/Akt of the VEGF gene to inhibit the
expression of the mTOR-HIF-1a-VEGF pathway and
increase vascular permeability.
In recent research, it has been proven that a new type of
metal complex can also participate in the regulation of
vascular permeability by controlling the release of NO.
Monti et al. [74] identified the protective effect of Ni(Pip-
NONO)Cl, a complex of Ni, in an experiment of in vitro
cultures of vascular endothelial cells. When the cultured
endothelial cells were exposed to IL-1β, the increase in
vascular permeability was realized by the Ni(PipNO-
NO)Cl, which suppressed the activity of cyclooxygenase-2
(COX-2) inhibitors to downregulate the expression of the
inducible nitric oxide synthase (iNOS). Silva et al. [75]
found that the Au nanoparticle (AuNPs) also regulated
the release of NO and the arterial vasodilation in rats. In
this study, a cluster formation that was generated by a
combination of AuNPs and a ruthenium complex (Ru-
4PySH), which is a donor of NO, reduced the release of
NO and increased vascular permeability.
Reducing vascular permeability by inhibiting the
phosphorylation of MLC
Atrial natriuretic peptide (ANP) can reduce the endothelial
leakage caused by injuries. Rho-specific guanine nucleotide
exchange factors (GEF-H1) released by microtubules can
stimulate the Rho pathway and increase vascular perme-
ability, while ANP can be used specifically to treat patho-
logical vascular leakage through regulating the function of
GEF-H1. In addition, ANP can also inhibit the phosphoryl-
ation of the MLC gene by inducing the inactivation of the
Rac-PAK1 dependent GEF-H1 to suppress the activity of
the Rho pathway [76]. Interestingly, ANP can be rapidly
degraded by neprilysin (NEP), which can be suppressed by
omapatrilat, thus reducing the leakage area of the arteries.
Ichiki et al. (2013) found that such a dual inhibitory effect
on NEP might be related to the ANP/cGMP pathway [77].
Chen et al. [78] found that ANP can impede the phosphor-
ylation of the MLC gene by inhibiting the GC/cGMP and
the TRPC6 pathways. Such potential efficacy on vascular
leakage was identified in an observational experiment that
sildenafil (i.e., Viagra) could enhance the effect of ANP on
the endothelium to improve the systemic endothelial
barrier functions.
In addition, pertussis toxin can offset the decrease in
the level of cAMP induced by hypoxia to reduce vascu-
lar leakage. Dexamethasone can also increase the level of
intracellular-soluble cAMP to suppress the phosphoryl-
ation of the MLC gene, which enhances the barrier func-
tions of endothelial cells. Maharjan et al. [79] found that
Sac-1004 can increase the content of cAMP, activate the
Rac pathway and improve the integrity of the endothelial
cell to enhance the endothelial barrier functions.
Preventing vascular leakage by protecting intercellular
junctions
It has been recently confirmed that Wnt and its
homologue, R-spondin, can also be used to treat
inflammation-related conditions in addition to the regula-
tion of embryonic development. Kannan et al. [80] found
that R-spondin3 (R-spo3) can maintain the integrity of
endothelial cell barriers by enhancing the junctions
between endothelial cells and preserving the positions of
VE-cadherin and F-actin in the cellular peripheral zone. It
has been confirmed that both inflammation and apoptosis
secondary to subarachnoid hemorrhage (SAH) are of sig-
nificance because of increases in vascular permeability.
Zhou et al. [81] indicated that urinary trypsin inhibitors
can exert anti-inflammatory and anti-apoptotic effects by
inhibiting the activity of the c-Jun N-terminal kinase
(JNK), nuclear factor-kappa B (NF-кB) and p53 genes to
slow the increase in vascular permeability secondary to
SAH. Moreover, diosmin also plays an important role in
maintaining the integrity of intercellular junctions and re-
ducing vascular permeability as a kind of natural flavonoid
glycoside. An experiment was performed to detect the
interruption of the blood-retina barrier by Evans blue
staining and assaying the structural variations in tight
junctions by transmission through an electron micro-
scope. Tong et al. [82] found that diosmin can increase
the content of ZO-1 and occludin in tight junctions and
can maintain the integrity of tight junctions to prevent an
increase in vascular permeability, which showed the
protective effect on retinal capillaries after ischemic
reperfusion.
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Conclusions
Although an increase in vascular permeability has been
proven to be necessary in various normal physiological
processes, such as embryonic vasculogenesis, formation
of the menstrual cycle and courses of wound-healing,
pathological increases in vascular permeability will result
in an increase of colloid osmotic pressure of the intersti-
tial space, which can seep liquid into the thoracic and
abdominal cavities and create a decrease in the effective
circulating blood volume. Meanwhile, various degrees of
leakage that occur in the lung can lead to hypoxemia,
which can further induce tissue hypoxia, creating a
vicious cycle that finally results in multiple organ dys-
function syndrome. Therefore, it is of great significance
to determine the most effective therapy for the treat-
ment of pathologically increased vascular permeability.
The current methods of prevention focus mainly on the
regulation of paracellular and transcellular signaling path-
ways or by blocking related inducing factors. Our research
recently found that the release of microparticles and the
membrane-protective mechanisms may also play import-
ant roles in the prevention of vascular leakage. Specific
regulatory mechanisms are currently being researched,
which will likely provide new therapeutic targets for the
treatment of vascular diseases. However, we must realize
that most current vascular leakage therapies target either
single signal or inducing factors, and comprehensively
treating vascular leakage to improve organic circulatory
functions after shock may be the future challenge regard-
ing the management of vascular permeability.
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